<DOC>
	<DOCNO>NCT01145430</DOCNO>
	<brief_summary>This phase I trial study side effect best dose veliparib give together pegylated liposomal doxorubicin hydrochloride treat patient ovarian cancer , fallopian tube cancer , primary peritoneal cancer come back period improvement , breast cancer spread part body . Veliparib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , liposomal doxorubicin hydrochloride , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving veliparib together liposomal doxorubicin hydrochloride may kill tumor cell .</brief_summary>
	<brief_title>Veliparib Pegylated Liposomal Doxorubicin Hydrochloride Treating Patients With Recurrent Ovarian Cancer , Fallopian Tube Cancer , Primary Peritoneal Cancer Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommended Phase II dose ABT-888 ( veliparib ) give combination pegylated liposomal doxorubicin ( pegylated liposomal doxorubicin hydrochloride ) ( PLD - 40 mg/m2 every 4 week ) patient ovarian breast cancer . SECONDARY OBJECTIVES : I . To determine toxicity profile ABT-888 plus PLD combination . II . To determine effect ABT-888 pharmacokinetics PLD . III . To determine efficacy ABT-888 plus PLD ovarian breast cancer . OUTLINE : This dose-escalation study veliparib . Patients receive veliparib orally ( PO ) twice daily ( BID ) day 1-14 pegylated liposomal doxorubicin hydrochloride intravenously ( IV ) 60 minute day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month 1 year every 6 month 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Histologically confirm diagnosis recurrent residual epithelial ovarian cancer , primary peritoneal carcinoma fallopian tube carcinoma , OR histologically confirm metastatic breast cancer , estrogen receptor ( ER ) negative , progesterone receptor ( PR ) negative , human epidermal growth factor receptor 2 ( HER2 ) /neu negative ( determined local pathology laboratory ) Prior chemotherapy : Ovarian cancer : patient prior PLD exposure eligible failure platinumcontaining chemotherapy ; 2 prior platinum contain regimen permit ; dose escalate cohort : patient already PLD also eligible receive PLD beyond 3 cycle without prohibitive ( i.e . grade 3 4 ) skin mucosal toxicity , show progressive disease compare compute tomography ( CT ) scan obtain 2 month earlier ; patient eligible spite progression baseline determine prematurely ( i.e. , applicable patient deem best interest continue receive PLD CT obtain 2 3 month show progression baseline ) Breast cancer : patient may receive 02 prior chemotherapy regimens metastatic disease ; breast cancer patient may receive prior PLD , eligible expand cohort A Interval prior chemotherapy registration breast ovarian cancer ; least 3 week interval last chemotherapy regimen registration , patient recover acute toxicity relate prior therapy ( 6 week last regiment include BCNU mitomycin C ) Dose escalate cohort : patient categorize follow stratum base upon prior PLD exposure : Stratum A patient ovarian cancer prior PLD exposure receive least 3 cycle PLD without prohibitive ( i.e . grade 3 4 skin toxicity ) progressive disease ; Stratum B : patient ovarian breast cancer prior PLD exposure Eastern Cooperative Oncology Group ( ECOG ) performance score 02 All potential subject evaluate whether breast cancer ( BRCA ) 12 test medically appropriate ; individual 10 % high risk BRCA12 mutation ( Myriad table www.myriad.com ) encourage ( require ) mutation test result know ; information regard mutation status ( positive [ include specific mutation ] , negative , unknown ) project risk mutation ( determine Myriad table ) collect time diagnosis Nonmeasurable and/or measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , abnormal cancer antigen ( CA ) 125 level ( patient ovarian cancer ) least 1.5 x normal document two independent measurement least 4 week apart Ability give voluntary informed consent comply treatment required test Ability tolerate oral medication Female subject age &gt; = 18 year ( male breast cancer eligible ) Absolute neutrophil count &gt; = 1500/mL Platelets &gt; = 100,000/mL Creatinine = &lt; 1.5 mg/dL Total bilirubin = &lt; 1.5 x institutional upper limit normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 3 x institutional upper limit normal ( = &lt; 5 x institutional upper limit normal evidence liver metastasis ) Left ventricular ejection fraction institutional low limit normal ( obtain within 8 week registration multigated acquisition [ MUGA ] scan echocardiogram ; test perform baseline repeat every 3 cycle therapy ) Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Known central nervous system ( CNS ) metastases active symptom , require anticonvulsive medication , steroid Prior chemotherapy ( except PLD Dose Escalation Cohorts ) investigational agent within 3 week prior registration Prior radiation therapy whole pelvis great amount marrowforming bone Prior current nongynecologic nonbreast malignancy within 5 year except nonmelanoma skin cancer Patients active severe infection ; know infection human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus , severe concurrent illness Patients nonmalignant intercurrent illness ( e.g . cardiovascular , pulmonary , central nervous system disease ) either poorly control currently available treatment , severity investigator deem unwise enter patient protocol Patients history seizure disorder require antiepileptic seizure episode within last 6 month Pregnant ( positive pregnancy test ) lactating ; unwillingness use effective mean contraception subject childbearing potential Evidence complete partial bowel obstruction unable take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>